#USA #Minneapolis #Bio-Techne #Leo System #Simple Western

Bio-Techne Launches the Leo System

Bio-Techne Corporation, a leader in biotechnology solutions, has officially commenced shipments of its groundbreaking Leo™ System, which utilizes Simple Western™ Technology. This innovative system is set to transform the landscape of protein analysis by offering remarkable improvements in both throughput and precision. With Leo, researchers can expect not just enhanced performance, but also a more efficient workflow from the initial stages of discovery to the commercialization of therapeutic treatments.

The Leo System significantly expands upon existing Simple Western platforms. Notably, it enables the simultaneous processing of up to 100 samples within just a three-hour timeframe. This capability represents a fourfold increase in throughput compared to the previous Jess™ Simple Western System, and it operates five times faster than its predecessors, Sally Sue™ and Peggy Sue™ systems. Such rapid performance is essential for laboratories looking to optimize their output while maintaining high standards of accuracy in protein quantification, which is crucial for regulatory submissions.

A key highlight of Leo is its ability to achieve the experimental size and reproducibility that is vital for analytical-grade protein quantitation. Researchers are increasingly finding that the precision this system offers can directly influence the quality of research results and their applications. Enhanced software, known as Compass for Simple Western, accompanies the instrument, providing advanced analytical capabilities and ensuring compliance with 21 CFR Part 11 regulations, which are critical for labs operating in highly regulated environments.

Will Geist, President of Bio-Techne's Protein Sciences Segment, emphasized the advantages of this new system, stating, "With Leo, scientists can achieve their development milestones faster and more efficiently, completing studies with fewer runs, operators, and instruments. This technology not only expedites the research process but also supports our customers in expediting advanced therapies to reach the market sooner."

Initial feedback from early adopters has been overwhelmingly positive. Beta testers have praised Leo for its robust performance, solid data quality, and a versatility that accommodates a wide array of applications. These include targeted protein degradation, clinical biomarker research, as well as assessments of gene therapy potency and quality control. Additionally, it’s well-suited for recombinant protein expression and other critical assays vital for today's detailed research requirements.

Overall, the Leo System represents a significant leap forward in bioanalytical workflows, enabling scientists to harness cutting-edge technology in their work. For those interested in exploring its capabilities further, additional data on Leo’s performance will be shared in an upcoming webinar, with registration details available through the Bio-Techne website.

As researchers continue to advance their studies and seek efficient solutions for complex protein analysis, the introduction of the Leo System marks a pivotal moment in the biotechnology sector, promising to facilitate a new era of innovation in scientific research.

For more details on the Leo System and its functionalities, visit Bio-Techne to stay updated and register for the informational webinar set to dive deeper into the system's features and benefits.